Federal Study Finds Lower Risk of Suicidal Thoughts in Popular Diabetes and Obesity Drugs
A recent federal study funded by the National Institutes of Health has found reassuring results for patients taking popular diabetes and obesity drugs. The study, which followed over 270,000 patients, found that drugs such as Ozempic and Wegovy have a lower risk of suicidal thoughts compared to other medications. This news comes as pharmaceutical companies like Novo Nordisk and Eli Lilly face scrutiny over the high cost of their obesity drugs.
The study, led by researchers at the University of North Carolina at Chapel Hill and the University of Chicago, was funded by the National Institute of Mental Health and the National Institute of Diabetes and Digestive and Kidney Diseases. It found that patients taking Ozempic or Wegovy had a 40% lower risk of experiencing suicidal thoughts or behaviors compared to those taking other diabetes and obesity medications. These findings are reassuring for patients and healthcare providers alike.
Dr. John Buse, a diabetes specialist at the University of North Carolina at Chapel Hill, who was not involved in the study, commented on its significance. “This is a very important paper,” Buse said. “It should reassure people that these drugs are not causing an increase in suicidal thoughts or behaviors.” This news is a relief for patients who may have been concerned about the potential side effects of these medications.
Meanwhile, in the stock market, Nvidia and Spotify have been outperforming the market, despite a tough first week. All eyes are now on NVDA as it prepares to make a presentation at CES. The company’s innovative technology and strong fundamentals have been driving its success.
On the other hand, pharmaceutical companies like Novo Nordisk and Eli Lilly are facing scrutiny over the high cost of their obesity drugs. These drugs, which can cost up to $1,000 per year per user, are being questioned by insurance providers and Medicare. The increased demand for these drugs has led to a doubling of costs for states, with projections showing even higher numbers in the future.
The success of Nvidia and Spotify, along with the reassuring findings of the federal study, highlight the value and resilience of these companies.
